Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 1/2018

01-02-2018 | Original Research Article

Molecular Characterization of FMR1 Gene by TP-PCR in Women of Reproductive Age and Women with Premature Ovarian Insufficiency

Authors: Deepika Delsa Dean, Sarita Agarwal, Deepa Kapoor, Kuldeep Singh, Chandra Vati

Published in: Molecular Diagnosis & Therapy | Issue 1/2018

Login to get access

Abstract

Background

Fragile X syndrome is caused by CGG repeat expansion mutation in the FMR1 gene. Normal alleles have 5–44 CGG repeats with AGG interruptions. The expanded gray zone (GZ) (45–54 repeats) and premutation (PM) (55–200 repeats) alleles are often uninterrupted and are unstably inherited in subsequent generations. The prevalence of PM and GZ carriers is high in the female population, at 1/66 and 1/113, respectively, and PM is associated with fertility problems in 20% of cases.

Objective

Our objective was to molecularly characterize CGG repeats and AGG interruption sequences in the FMR1 gene in women of reproductive age and in women with premature ovarian insufficiency (POI).

Materials and Methods

We conducted molecular analysis of the FMR1 gene from 300 women of reproductive age and 140 women with POI using triplet primed-polymerase chain reaction. This enabled us to identify carriers and to document CGG repeat size and the AGG interruption pattern.

Results

In women of reproductive age, 1.7% were GZ carriers and 0.3% were PM carriers; in women with POI, 3.6% were GZ carriers and 2.14% were PM carriers. The frequency of GZ and PM carriers did not significantly differ between the cohorts (Fisher’s exact test: p < 2.23 for GZ vs. control and p < 0.101 for PM vs. control). Carriers received genetic counselling; family screening identified an additional seven carriers.

Conclusion

We documented preliminary data on the prevalence of GZ and PM carriers among the studied cohorts. The identification of PM carriers among women with POI serves a dual purpose of recognizing a cause for ovarian dysfunction and enabling genetic counselling, which will help carriers when making reproductive decisions.
Appendix
Available only for authorised users
Literature
1.
2.
Ruiz LR, Borgarello MQ, Aytes LB, Escoda CG. Frile X-syndrome: literature review and report of two cases. Med Oral. 2009;14:9.
3.
de Vries BBA, Wiegers AM, Smits APT, Mohkamsing S, Duivenvoorden HJ, Fryns JP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet. 1996;58:1025–32.PubMedPubMedCentral
4.
Warren ST, Sherman SL. The fragile X syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease, vol. 8. New York: McGraw Hill; 2001. p. 1257–89.
5.
6.
Tassone F, Beilina A, Carosi C, Albertosi S, Bagni C, Li L, et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA. 2007;13:555–62.CrossRefPubMedPubMedCentral
7.
Bennetto L, Pennington BF, Porter D, Taylor AK, Hagerman RJ. Profile of cognitive functioning in women with the fragile X mutation. Neuropsychology. 2001;15:290–9.CrossRefPubMed
8.
Reiss AL, Freund L, Abrams MT, Boehm C, Kazazian H. Neurobehavioral effects of the fragile X premutation in adult women: a controlled study. Am J Hum Genet. 1993;52:884–94.PubMedPubMedCentral
9.
Nolin SL, Brown WT, Glicksman A, George EH Jr, Alice DG, Amy S, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet. 2003;72(2):454–64.CrossRefPubMedPubMedCentral
10.
Nolin SL, Lewis FA, Ye LL, Houck GE, Glicksman AE, Limprasert P, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet. 1996;59:1252–61.PubMedPubMedCentral
11.
Marsha MS, Mei WB, Jinkuk H, Matthew M, Greenberg J, Mande D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet Part B Neuropsychiatr Genet. 2012;159(5):589–97.
12.
Tassone F, Iong KP, Tong T-H, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.CrossRefPubMedPubMedCentral
13.
Baskaran S, Naseerullah MK, Manjunatha KR, Chetan GK, Arthi R, Rao GV, et al. Triplet repeat polymorphism and fragile X syndrome in the Indian context. Indian J Med Res. 1998;107:29–36.PubMed
14.
Marozzi A, Vegetti W, Manfredini E, Tibiletti MG, Testa G, Crosignani PG, et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod. 2000;15:197–202.CrossRefPubMed
15.
16.
Welt C, Smith P, Taylor A. Evidence of early ovarian aging in Fragile X premutation carriers. J Clin Endocrinol Metab. 2004;89:4569–74.CrossRefPubMed
17.
Allen EG, Sullivan AK, Marcus M, Small C, Dominguez C, Epstein MP, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod. 2007;22:2142–52.CrossRefPubMed
18.
Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet. 2006;14:253–5.CrossRefPubMedPubMedCentral
19.
Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005;20:402–12.CrossRefPubMed
20.
Corrigan EC, Raygada MJ, Vanderhoof VH, Nelson LM. A woman with spontaneous premature ovarian failure gives birth to a child with fragile X syndrome. Fertil Steril. 2005;84:1508.CrossRefPubMed
21.
Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53:804–10.CrossRefPubMed
22.
American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 605: carrier screening for fragile X syndrome. Obstet Gynecol. 2014;116(4):1008–10.
23.
Dean DD, Srinivasan M, Sarita A. Fragile X syndrome: current insight. Egypt J Med Hum Genet. 2016;17(4):303–5.CrossRef
24.
Todorov T, Todorova A, Georgieva B, Mitev V. A unified rapid PCR method for detection of normal and expanded trinucleotide alleles of CAG repeats in huntington chorea and CGG repeats in fragile X syndrome. Mol Biotechnol. 2010;45(2):150–4.CrossRefPubMed
25.
Srinivasan M, Dean DD, Agarwal S. Molecular screening of intellectually disabled and premature ovarian failure cases for CGG repeat expansion at FMR1 locus: implication of combined triplet repeat primed polymerase chain reaction and methylation-specific polymerase chain reaction analysis. Neurol India. 2016;64(6):1175–9.CrossRef
26.
McConkie-RA Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns. 2005;14:249.CrossRef
27.
Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164A(7):1648–58.CrossRefPubMed
28.
Pastore LM, Morris WL, Karns LB. Emotional reaction to fragile X premutation carrier tests among infertile women. J Genet Couns. 2008;17(1):84–91.CrossRefPubMed
29.
Karla LB, Margo RF, Wendy PR. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005;117(4):76–382.
30.
Streuli I, Fraisse T, Ibecheole V, Moix I, Morris MA, de Ziegler D. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency. Fertil Steril. 2009;92:464–70.CrossRefPubMed
31.
Karimov CB, Moragianni VA, Cronister A, Srouji S, Petrozza J, Racowsky C, et al. Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum Reprod. 2011;26(8):2077–83.CrossRefPubMed
32.
Voorhuis M, Onland-Moret NC, Janse F, Ploosvan Amstel HK, Goverde AJ, Lambalk CB, et al. The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency. Hum Reprod. 2014;29(7):1585–93.CrossRefPubMed
33.
Bennett CE, Conway GS, Macpherson JN, Jacobs PA, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum Reprod. 2010;25:1335–8.CrossRefPubMedPubMedCentral
34.
Nolin SL, Glicksman A, Ersalesi N, Dobkin C, Brown WT, et al. Fragile X Full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. Genet Med. 2014;17(5):358–64.CrossRefPubMed
35.
Nolin SL, Sah S, Glicksman A, Sherman SL, Allen E, et al. Fragile X AGG analysis provides new risk predictions for 45–69 repeat alleles. Am J Med Genet A. 2013;161A(4):771–8.CrossRefPubMed
36.
Yrigollen CM, Martorell L, Durbin-Johnson B, et al. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. J Neurodev Disord. 2014;6(1):24.CrossRefPubMedPubMedCentral
37.
Latham GJ, Coppinger J, Hadd AG, Nolin SL. The role of AGG interruptions in fragile X repeat expansions: a twenty-year perspective. Front Genet. 2014;5:244.CrossRefPubMedPubMedCentral
38.
Kline JK, Kinney AM, Levin B, Brown SA, Hadd AG, Warburton D. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause (New York, NY). 2014;21(7):740–8.CrossRef
39.
Hagit TA, Lina BV, Nurit M, Bella D, Sophie E, Valerie D, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet. 2001;69(2):351–60.CrossRef
40.
Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn. 2000;20:611–4.CrossRefPubMed
41.
Mallolas J, Duran M, Sanchez A, Jimenez D, Castellvi-Bel S, Rife M, et al. Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause. 2001;8:106–10.CrossRefPubMed
42.
Bussani C, Papi L, Sestini R, Baldinotti F, Bucciantini S, Bruni V, Scarselli G. Premature ovarian failure and fragile X premutation: a study on 45 women. Eur J Obstet Gynecol Reprod Biol. 2004;112(2):189–91.CrossRefPubMed
43.
Indhumathi N, Singh D, Chong SS, Thelma BK, Arabandi R, Srisailpathy CRS. Fragile X CGG repeat variation in tamil nadu, south India: a comparison of radioactive and methylation-specific polymerase chain reaction in CGG repeat sizing. Genet Test Mol Biomark. 2012;16(2):113–22.CrossRef
44.
Murray A, Schoemaker MJ, Bennett CE, Sarah E, James NM, Michael J, et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet Med. 2014;16(1):19–24.CrossRefPubMed
Metadata
Title
Molecular Characterization of FMR1 Gene by TP-PCR in Women of Reproductive Age and Women with Premature Ovarian Insufficiency
Authors
Deepika Delsa Dean
Sarita Agarwal
Deepa Kapoor
Kuldeep Singh
Chandra Vati
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 1/2018
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-017-0305-9

Other articles of this Issue 1/2018

Molecular Diagnosis & Therapy 1/2018 Go to the issue

Leading Article

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

Original Research Article

Polymorphisms in Genes Involved in the Leptin-Melanocortin Pathway are Associated with Obesity-Related Cardiometabolic Alterations in a Southern Chilean Population

Review Article

Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes

Review Article

Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors

Review Article

Pharmacogenetics of Methadone Response

Original Research Article

Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits